ARTICLE | Clinical News
Zibotentan fails prostate cancer Phase III
September 28, 2010 12:03 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) said once-daily oral zibotentan ( ZD4054) plus standard of care (SOC) missed the primary endpoint of significantly improving overall survival vs. placebo plus SOC i...